GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Price-to-Free-Cash-Flow

Ultimovacs ASA (OSL:ULTI) Price-to-Free-Cash-Flow : N/A (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Price-to-Free-Cash-Flow?

As of today (2024-05-01), Ultimovacs ASA's share price is kr6.98. Ultimovacs ASA's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr-5.55. Hence, Ultimovacs ASA's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Ultimovacs ASA's Price-to-Free-Cash-Flow or its related term are showing as below:

OSL:ULTI's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.685
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Ultimovacs ASA's Free Cash Flow per Share for the three months ended in Dec. 2023 was kr-1.23. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr-5.55.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -13.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -13.80% per year.

During the past 9 years, Ultimovacs ASA's highest 3-Year average Free Cash Flow per Share Growth Rate was -7.00% per year. The lowest was -28.60% per year. And the median was -13.70% per year.


Ultimovacs ASA Price-to-Free-Cash-Flow Historical Data

The historical data trend for Ultimovacs ASA's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Price-to-Free-Cash-Flow Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

Ultimovacs ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ultimovacs ASA's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Ultimovacs ASA's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultimovacs ASA's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Price-to-Free-Cash-Flow falls into.



Ultimovacs ASA Price-to-Free-Cash-Flow Calculation

Ultimovacs ASA's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=6.98/-5.547
=N/A

Ultimovacs ASA's Share Price of today is kr6.98.
Ultimovacs ASA's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.55.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Ultimovacs ASA  (OSL:ULTI) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Ultimovacs ASA Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA (OSL:ULTI) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (OSL:ULTI) Headlines